60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
1.300
0.00 (0.00%)
At close: Nov 6, 2025, 4:00 PM EST
1.300
0.00 (0.00%)
After-hours: Nov 6, 2025, 6:19 PM EST
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $307.87K in the quarter ending June 30, 2025, with 144.93% growth. This brings the company's revenue in the last twelve months to $984.49K, up 128.70% year-over-year. In the year 2024, 60 Degrees Pharmaceuticals had annual revenue of $681.35K with 168.70% growth.
Revenue (ttm)
$984.49K
Revenue Growth
+128.70%
P/S Ratio
1.39
Revenue / Employee
$328,165
Employees
3
Market Cap
5.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 681.35K | 427.77K | 168.70% |
| Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
| Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
| Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
| Dec 31, 2020 | 2.55M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SXTP News
- 22 days ago - 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results - GlobeNewsWire
- 4 months ago - 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering - GlobeNewsWire
- 4 months ago - 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering - GlobeNewsWire